Allergan is still on the acquisition trail following its failed merger with Pfizer, spending $85 million to acquire privately-held Topokine Therapeutics and its late-stage product for under-eye bags.
US drugmaker AbbVie has agreed to buy struggling Allergan in a $63 billion deal that continues a slew of multibillion dollar takeovers in the biopharma sector this year. AbbVie is stumping up more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback